Meet Pier 70's Venture Advisor, Jenn Bennett. Jenn is a brilliant technologist with a profound understanding of how technology can revolutionize industries, from manufacturing to health. Her impressive journey includes visionary companies like CISCO and GE, and she currently leads Google’s CTO Office Innovation and Incubation engineering team. In this role, she tackles complex technical challenges with Cloud's strategic customers, fostering innovation through collaborative experimentation and pushing the boundaries of real-world applications. Jenn's expertise is particularly vital in the Health sector, where her vision and "imagineering" will be instrumental in building the #FutureofHealth. She also advises CapitalG, a Google investment arm, giving her a front-row seat to companies leveraging technology for scalable innovation. With a background in bioengineering from the University of Pittsburgh and Cornell University, Jen brings invaluable vision and command of future-forward technologies. We are delighted to have her guidance as our companies innovate with #AIforhealthcare! Preetha Ram Shaun Hawkins R. Miller Adams Minnie Sarwal Stephanie Bousheri Phil Nwafor Tamir Meiri David Wilkes Dennis Liotta Onix Ramirez Jiafeng (Jeff) Geng, PhD, JD Fatima Cody Stanford Ashwin Ram
Pier 70 Ventures
Venture Capital and Private Equity Principals
Seattle, Washington 982 followers
VENTURE BOLDLY
About us
At Pier 70, we invest in impact-driven innovation. We find and fund disruptive technologies with the potential to shake up the status quo in healthcare. Entrepreneurs choose Pier 70 for capital and counsel, and we help them build diverse teams well-positioned to achieve financial success. Our success will be measured by their success and the collective value that we create.
- Website
-
https://pier70ventures.com/
External link for Pier 70 Ventures
- Industry
- Venture Capital and Private Equity Principals
- Company size
- 2-10 employees
- Headquarters
- Seattle, Washington
- Type
- Partnership
- Founded
- 2017
- Specialties
- Early Stage, Growth Stage, Women Entrepreneurs, Black Entrepreneurs, Advanced Mobility Technologies, Aerospace, AR/VR, Drone, Satellites, UAM, and Venture Capital
Locations
-
Primary
Get directions
Seattle, Washington 98121, US
Employees at Pier 70 Ventures
-
Shaun Hawkins
Managing Partner
-
Preetha Ram
VC. Board Member. CEO & CTO. Innovator & Entrepreneur | Health| Life Sciences| Education|Technology | TedX Speaker. Talks about #AIInHealth…
-
Frederick Grimm
Venture Partner at Pier 70 Ventures
-
Leland Melvin
Board Director at BWX Technologies INC
Updates
-
Congratulations to DocSpera on yet another win!
🚀 New Partnership Alert: PayrHealth + DocSpera We’re excited to announce our strategic partnership with DocSpera, the intelligent surgical coordination platform, to help ASCs meet new CMS patient outcomes reporting requirements and turn compliance into opportunity. Beginning in 2027, CMS will require ASCs to capture and report patient-reported outcomes for at least 45% of Medicare procedures. With penalties as high as 2% of revenue for non-compliance, centers must start building benchmarks now. Together, PayrHealth and DocSpera will deliver an automated, end-to-end solution that helps ASCs: ✅ Identify eligible patients ✅ Capture and track outcomes through mobile-friendly tools ✅ Automate CMS reporting and reduce admin burden ✅ Leverage outcome data to strengthen payor negotiations Learn more about how we’re helping ASCs prepare today for tomorrow’s requirements in the press release: https://lnkd.in/e5U7aFPS #ASC #HealthcareInnovation #Compliance #CMS #PatientOutcomes #HealthcarePartnership
-
Meet Pier 70’s Venture Advisors: Dr. Minnie Sarwal Minnie Sarwal is a true powerhouse in the life sciences. Minnie's background is exemplary and extraordinary. As an MD, PhD, and FRCS-trained surgeon from the prestigious University of Cambridge, she brings an unparalleled blend of scientific rigor and clinical expertise to our team. Her experiences as an exited entrepreneur (her company Organ-I, spun out of Stanford University was purchased by Immucor, Inc.) in medical devices and her leadership role at the University of California, San Francisco's Transplant Initiative give her a unique insight into what it takes to bring a groundbreaking idea from the lab to the patient. Minnie's deep involvement in the venture ecosystem extends to being a founding member of the UCSF Rosenman Institute, a community dedicated to helping medical device entrepreneurs bring their technologies from concept to commercialization. She is also an External Advisory Board member at Houston Methodist, one of the nation’s leading health systems and academic medical centers. She serves on the FDA Science Board, advising the FDA commissioner on key advances in food and science, has served on Editorial Boards for various scientific journals and serves as Chair on NIH and Department of Defense sections. Minnie has a finger on the pulse of the latest scientific breakthroughs, which will be invaluable for us at Pier 70 Ventures as we continue to invest in the next generation of innovators and build the #Futureofhealth. Preetha Ram Shaun Hawkins R. Miller Adams Fatima Cody Stanford David Wilkes Stephanie Bousheri Jenn Bennett Dennis Liotta Onix Ramirez Jiafeng (Jeff) Geng, PhD, JD
-
-
We're proud to have our Managing Partner, Preetha Ram, Ph.D., representing Pier 70 Ventures at #EPPICCON! Preetha will be sharing our fund's perspective on operationalizing AI to truly transform the #FutureofHealth. We believe the critical challenge for Pharma lies in maximizing the rigorous ROI of AI from lab to market. Don't miss her insights. #VentureBoldly #HealthTech #AI #DigitalHealth Shaun Hawkins R. Miller Adams Minnie Sarwal Stephanie Bousheri Phil Nwafor
📅 Register Now: EPPICON 2025 is approaching! Insight packed Digital Health & AI panel on 'Operationalizing AI in BioPharma' at EPPICON 2025 Abhishek Jha Preetha Ram David Shames Venkatesh Moktali, PhD Preetha Ram Abhishek Jha David Shames Venkatesh Moktali, PhD 📌 Reserve your spot and take advantage of the registration discount (Use coupon EPPICON_50%): 👉https://lnkd.in/gB636VX4 October 11 2025 Crowne Plaza Foster City, CA EPPIC Global California Life Sciences (CLS) MBC BioLabs
-
-
Congratulations to Cody Simmons and the DermaSensor, Inc.team on thier recent Series B close. We are delighted to be building the #FutureofHealth with Dermasensor and their AI-enabled skin cancer diagnostic tool that is skincoloragnostic! #AIforHealth Shaun Hawkins Preetha Ram R. Miller Adams Fatima Cody Stanford Jenn Bennett David Wilkes Dennis Liotta Minnie Sarwal Stephanie Bousheri Robert (Bob) Balk Phil Nwafor
🚀 Big news from DermaSensor! We’ve raised $16 million in Series B funding, bringing our total to $43 million — fueling the expansion of our FDA cleared, handheld skin cancer detection device. Since launching in mid-2024, we've surpassed 20,000 lesions scanned with an incredible 117% quarterly growth rate, helping frontline physicians detect cancer earlier and more accurately. Featured in publications like Nature and media outlets like TIME’s Best Inventions of 2024, our AI-powered optical spectroscopy device is the first and only of its kind approved for primary care use in the U.S. We're proud to be transforming skin cancer detection and excited for what’s next. Thank you to our investors — including Pier 70 Ventures, Kern Venture Group, GenHenn Capital, and more — for believing in our mission. Read more: https://lnkd.in/gWC9mCip #SkinCancerAwareness #HealthTech #FDAcleared #AIinHealthcare #DigitalHealth #PrimaryCare #SeriesB #MedTech #Innovation #DermaSensor
-
-
Meet Pier 70’s Venture Advisors: Dr. Fatima Cody Stanford Dr. Fatima Cody Stanford is a true pioneer in medicine, and her background is a testament to her unique and impactful career. As an MD, MPH, and MPA from Harvard Medical School, and with an MBA from the Quantic School of Business and Technology, this Emory University alum brings an unparalleled blend of clinical expertise, public health knowledge, policy acumen, and business insight to our firm. A world-renowned obesity medicine physician-scientist at Harvard Medical School and Massachusetts General Hospital, she has dedicated her career to addressing one of the most complex and misunderstood health challenges of our time. Dr. Stanford is a powerful advocate for redefining obesity as a chronic disease rather than a character flaw. Her work at the intersection of medicine, public health, and policy is aimed at tackling systemic health disparities and eliminating the bias and stigma that have historically plagued patient care. We believe this holistic, problem-solving approach is exactly what it takes to build enduring companies. Her deep insights into the science, clinical practice, and policy surrounding drugs, devices, and digital health will be invaluable for us at Pier 70 Ventures. We are incredibly excited to have her on our team as we continue to invest in innovators who are building the #Futureofhealth. Preetha Ram Shaun Hawkins R. Miller Adams #innovation #healthcare #WomeninStem #startups #venturecapital
-
-
The future of healthcare isn't about AI vs. humans—it's about how AI augments the brilliant work of clinicians and researchers. That's why we're thrilled that our Partner, Preetha Ram, will be sharing her insights on this critical topic at BioTechX this week at a keynote session and also at a panel. She'll be diving deep into how AI is revolutionizing care and accelerating clinical trials, a core thesis for our firm's early-stage investments. At Pier 70 Ventures, we believe the most impactful companies won't just build great technology; they'll build solutions that integrate seamlessly with the healthcare system to solve real problems for clinicians and patients. Looking forward to engaging with fellow innovators and founders. Let’s build the #FutureofHealth together. Shaun Hawkins R. Miller Adams Robert (Bob) Balk Anna Abiola #BiotechX #AIinHealthcare #VentureCapital #DigitalHealth #AIinDrugDiscovery Conference: https://lnkd.in/gCPaxRWw Date: September 16, 2025
-
-
Congratulations to the GeniPhys team, Andy Eibling, CEO and Sherry Harbin, Founder, the scientific genius behind the innovation and the team for this important milestone! Preetha Ram Shaun Hawkins R. Miller Adams Robert (Bob) Balk
GeniPhys is proud to announce we have received 510(k) clearance for our flagship product, Collymer Self-Assembling Scaffold (SAS) for applications in advanced wound care. This milestone event was made possible through the collaborative efforts of the GeniPhys team and now paves the way for commercial launch, where Collymer SAS has the potential to address critical unmet needs for millions of patients. The collagen polymer platform is a novel solution in the wound care market developed to overcome limitations associated with conventional implantable materials. With its ability to adapt to complex wound geometries, Collymer SAS offers a meaningful advancement for both patients and clinicians. GeniPhys is currently raising capital to support commercialization efforts and is also pursuing strategic partnerships to accelerate its product launch and adoption in the advanced wound care market. https://lnkd.in/g_rUm48k
-
-
The promise of #AIforHealth and #ImageAIcomes to fruition in this FDA cleared device for early detection of skin cancer, agnostic of skin color. Congratulations to Cody Simmons and Maurice R. Ferre M.D. for DermaSensor, Inc. and empowering earlier, faster and more accurate diagnosis. Preetha Ram Shaun Hawkins R. Miller Adams Robert (Bob) Balk
VC. Board Member. CEO & CTO. Innovator & Entrepreneur | Health| Life Sciences| Education|Technology | TedX Speaker. Talks about #AIInHealth, #WomeninTech, #Entrepreneurs, #Diversity
Why We Invested in DermaSensor We're thrilled to announce Pier 70 Ventures' investment in DermaSensor, a company revolutionizing skin cancer detection! The DermaSensor team: Frank Rios, Area Sales Director, Kiran Chatha, Associate Medical Director, Jacqueline Barberena, Senior Marketing Director, Cody Simmons, CEO, Ruth Stachura, MBA, National Sales Director The Challenge::Skin cancer is the most prevalent cancer in the US, with millions diagnosed annually. Traditional visual inspection often leads to missed or late diagnoses, which can be as high as 30% in some cases. This is especially critical for individuals with brown and black skin, who face an even greater risk of missed or delayed diagnosis. Black patients are more than three times as likely to be diagnosed at a later stage (Stage 3 or 4) than white patients. DermaSensor's Solution: DermaSensor, Inc. offers an FDA-cleared, non-invasive handheld device that uses spectroscopy and AI to assess skin lesions. This technology provides a diagnosis with >90% accuracy in minutes, empowering primary care physicians to detect potential skin cancers earlier, regardless of skin color. This leads to improved patient outcomes and addresses health equity gaps. The FDA recognizes the potential of AI-enabled devices and has authorized over 950 AI/ML-enabled medical devices as of October 2024. The Team: DermaSensor is led by an experienced team: Maurice R. Ferre M.D. Ferre, Chairman & Co-Founder, serial entrepreneur with a track record in medical technology, including leading MAKO Surgical Corp. Cody Simmons, CEO & Co-Founder, bioengineer and entrepreneur with experience in bringing health technologies to market. An experienced leadership team in medical, commercial, and operational domains. Co-Investors: We're excited to partner with Harmonix Fund, Lateral Capital Ventures, GenHenn Capital, Brown Angel Group, Wealthing VC Club and other investors. We believe DermaSensor's technology and team will significantly impact the fight against skin cancer. We're proud to support their mission to improve early detection and save lives. #HealthTech #VentureCapital #SkinCancerDetection #AIinHealthcare #Investment #Pier70Ventures #DermaSensor Shaun Hawkins Alicia Castillo Holley, PhD, MBA, MSci
-
-
#AIforHealth is here and solving a critical problem for millions of anxious parents everywhere, is OtoNexus Medical Technologies with Caitlin Cameron at the helm. #FutureofHealth is coming. Shaun Hawkins R. Miller Adams Robert (Bob) Balk Preetha Ram
VC. Board Member. CEO & CTO. Innovator & Entrepreneur | Health| Life Sciences| Education|Technology | TedX Speaker. Talks about #AIInHealth, #WomeninTech, #Entrepreneurs, #Diversity
At Pier 70 Ventures Ventures, we’re deeply committed to supporting innovation and the #Futureofhealthcare, backing technologies that leverage AI to transform patient outcomes. We are thrilled to announce our investment in OtoNexus Medical Technologies and their revolutionary Novoscope device. The Problem: Otitis Media, or middle ear infections, affects 90% of children under 4, making it the leading cause of antibiotic prescriptions and surgery in this age group. Traditional diagnostic methods are often subjective, leading to antibiotic overuse and contributing to the growing crisis of antibiotic resistance. This matters because it impacts the health of our children and has far-reaching implications for public health. OtoNexus has developed the Novoscope, a handheld device that utilizes a proprietary air ultrasound technology and advanced #AI algorithms to accurately differentiate between viral and bacterial ear infections in seconds. This enables targeted treatment, reducing unnecessary antibiotic use and improving patient outcomes. We believe OtoNexus represents the future of diagnostic medicine. Their innovative technology addresses a critical unmet need, has significant market potential, and aligns perfectly with our focus on AI-enabled technologies. We are incredibly impressed with the leadership at OtoNexus. Caitlin Cameron, Chair, CEO, and Co-founder: A seasoned leader with over 30 years of experience in life sciences and biotech in C-level roles. She specializes in building high-performing start-up companies, and has received several nominations for one of the 100 Best Places to Work in Washington. Mark Moehring, PhD, CSO and Co-founder: An innovation leader in ultrasound technology, Dr. Moehring has over three decades of experience in signal processing and designing medical ultrasound instruments. John Alleman, CTO: With decades of experience in medical device development and regulatory approval. Mr. Alleman is a retired Navy submarine officer with a deep background in medical device product development, quality systems, and manufacturing operations. Gina Kelly, CPMO: An experienced medical device expert with 30+ years of experience in the ultrasound industry, working previously in leadership roles at ATL, Philips Healthcare, and Fujifilm SonoSite, specializing in product strategy and commercialization. We are delighted to invest with progressive organizations like Keiretsu Forum Northwest and Children's Minnesota. Supporting strong women's leadership is important to us. We believe the Novoscope will make a profound difference in the lives of countless children and families worldwide. We’re proud to be part of this journey. #HealthcareInnovation #AIinMedicine #MedicalTechnology #Investment #Pier70Ventures #OtoNexus #AntibioticResistance #WomenInLeadership #HealthTech #MedTech #FutureOfHealthcare Shaun Hawkins R. Miller Adams Robert (Bob) Balk
-